Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study

Intravitreal Aflibercept Treatment Strategies in Routine Clinical Practice of Neovascular Age-Related Macular Degeneration in Belgium: A Retrospective Observational Study

Abstract Introduction STELLAR was a Belgian, multicentre, retrospective, observational chart review that described the utilization (number of injections and treatment regimen) and effectiveness of intravitreal aflibercept (IVT-AFL) in patients with anti-vascular endothelial growth factor (VEGF) trea...

Full description

Bibliographic Details
Main Authors:	Joke Ruys, Els Mangelschots, Julie Jacob, Filip Mergaerts, Alexandra Kozyreff, Werner Dirven
Format:	Article
Language:	English
Published:	Adis, Springer Healthcare 2020-09-01
Series:	Ophthalmology and Therapy
Subjects:	Aflibercept Age-related macular degeneration Intravitreal injections Retina Retina—Medical therapies
Online Access:	https://doi.org/10.1007/s40123-020-00300-7

Similar Items

Switching to aflibercept among patients with treatment-resistant neovascular age-related macular degeneration: a systematic review with meta-analysis
by: Spooner K, et al.
Published: (2017-01-01)

Worsening anatomic outcomes following aflibercept for neovascular age-related macular degeneration in eyes previously well controlled with ranibizumab
by: Nudleman E, et al.
Published: (2016-06-01)

Choroidal structural changes determined by the binarization method after intravitreal aflibercept treatment in neovascular age-related macular degeneration
by: Emine Temel, et al.
Published: (2021-08-01)

CFH Y402H polymorphism and response to intravitreal Ranibizumab in brazilian patients with neovascular age-related macular degeneration
by: Carlos Eduardo Veloso, et al.

Clinical Application of Intravitreal Aflibercept Injection for Diabetic Macular Edema Comparing Two Loading Regimens
by: Yoo-Ri Chung, et al.
Published: (2023-03-01)

Intravitreal Aflibercept versus Laser Photocoagulation in Asian Patients with Diabetic Macular Edema: The VIVID-East Study
by: Chen YX, et al.
Published: (2020-03-01)

XTEND: Two-Year Results from a Global Observational Study Investigating Proactive Dosing of Intravitreal Aflibercept in Neovascular Age-Related Macular Degeneration
by: Jean-François Korobelnik, et al.
Published: (2024-01-01)

Impact of intravitreal aflibercept dosing regimens in treatment-naïve patients with neovascular age-related macular degeneration: 2-year results of RAINBOW
by: Michel Weber, et al.
Published: (2020-05-01)

Intravitreal Brolucizumab in Patients with Aflibercept-Resistant Neovascular Age-Related Macular Degeneration
by: Ashwin Gupta, et al.
Published: (2022-01-01)

Real-World Experience Using Intravitreal Brolucizumab Alone or in Combination with Aflibercept in the Management of Neovascular Age-Related Macular Degeneration
by: Mehta N, et al.
Published: (2023-02-01)

Evaluation of aflibercept and ziv-aflibercept binding affinity to vascular endothelial growth factor, stability and sterility after compounding
by: Julia de Lima Farah, et al.
Published: (2018-10-01)

Intravitreal aflibercept in neovascular age-related macular degeneration previously treated with ranibizumab
by: Rachel Hui Fen Lim, et al.
Published: (2017-03-01)

One-year results of switching to aflibercept for persistent diabetic macular edema resistant to bevacizumab
by: Mahmoud Alaa Abouhussein, et al.
Published: (2021-01-01)

Efficacy of Aflibercept versus Ranibizumab in the treatment of diabetic macular edema
by: Xiu-Xian Wang, et al.
Published: (2021-12-01)

Idiopathic Macular Telangiectasia Type 1 treated with Intravitreal Ranibizumab and Laser Photocoagulation
by: Inês Martins de Almeida, et al.
Published: (2015-09-01)

Effects of Intravitreous Aflibercept Injection in Pachychoroid Neovasculopathy: Comparison with Typical Neovascular Age-Related Macular Degeneration
by: Elfandi S, et al.
Published: (2021-04-01)

Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
by: Kendra A. Klein, et al.
Published: (2017-04-01)

Intravitreal Aflibercept for the Treatment of Diabetic Macular Edema in Routine Clinical Practice: Results from the 24-Month AURIGA Observational Study
by: Simone Donati, et al.
Published: (2023-11-01)

Evaluation of early versus late intravitreal bevacizumab injection in the treatment of macular edema secondary to branch retinal vein occlusion
by: Hesham A Enany
Published: (2018-01-01)

Intravitreal Aflibercept Therapy in Intravitreal Bevacizumab/Ranibizumab Treatment-resistant Exudative Age-related Macular Degeneration
by: Neslihan Sevimli, et al.
Published: (2023-09-01)

Effectiveness of the Use of Three-Dose Intravitreal Ziv-Aflibercept in the Management of Diabetic Macular Edema in a Real-Life Setting
by: Munayco-Guillén F, et al.
Published: (2023-04-01)

Progress of Aflibercept of clinical application for neovascular age-related macular degeneration
by: Yun-Yan Zheng, et al.
Published: (2021-10-01)

Pharmacokinetic and Pharmacodynamic Rationale for Extending VEGF Inhibition Increasing Intravitreal Aflibercept Dose
by: Daniele Veritti, et al.
Published: (2023-05-01)

Comparison of intravitreal ziv-aflibercept and bevacizumab monotherapy in treatment-naive polypoidal choroidal vasculopathy
by: Sumit Randhir Singh, et al.
Published: (2019-01-01)

The effect of ocular rinse volume on surface irritation after povidone-iodine preparation for intravitreal injections: a randomized controlled trial
by: Farzad Jamshidi, et al.
Published: (2023-09-01)

Monthly Alternating Injections of Aflibercept and Bevacizumab for Neovascular Age-Related Macular Degeneration
by: Junyeop Lee, et al.
Published: (2022-03-01)

Intravitreal aflibercept following treat and extend protocol versus fixed protocol for treatment of neovascular age-related macular degeneration
by: Alaa Din Abdin, et al.
Published: (2021-12-01)

Twelve-week dosing with Aflibercept in the treatment of neovascular age-related macular degeneration
by: Garweg JG
Published: (2019-07-01)

Switching to ziv-aflibercept in resistant diabetic macular edema non responsive to ranibizumab injection
by: Amin E. Nawar, et al.
Published: (2022-06-01)

Aflibercept monotherapy or bevacizumab first for diabetic macular edema
by: Avner Hostovsky, et al.
Published: (2024-01-01)

Renal thrombotic microangiopathy and nephrotic proteinuria induced by intravitreal injection of aflibercept for diabetic macular edema
by: Yawara Kikuchi, et al.
Published: (2022-10-01)

Impact of Delayed Intravitreal Anti-Vascular Endothelial Growth Factor (VEGF) Therapy Due to the Coronavirus Disease Pandemic on the Prognosis of Patients with Neovascular Age-Related Macular Degeneration
by: Jae-Gon Kim, et al.
Published: (2022-04-01)

Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD
by: Dorota Luksa, et al.
Published: (2021-11-01)

Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
by: Paulose R, et al.
Published: (2016-09-01)

One-Year Outcome of Aflibercept Intravitreal Injection in Vitrectomized Eyes with Diabetic Macular Edema
by: Tran THC, et al.
Published: (2021-05-01)

A customized regimen of intravitreal aflibercept for the treatment of choroidal neovascularization secondary to different chorioretinal diseases
by: Magdy Moussa, et al.
Published: (2023-01-01)

Effects of Aflibercept on ion channel of retinal Müller cell membrane cultured <i>in vitro</i>
by: Qi-Feng Lei, et al.
Published: (2019-04-01)

Deformation of Aflibercept and Ranibizumab Syringes Causes Variation in Intravitreal Injection Volume and Risks Retinal Tear Formation
by: Joseph J. Raevis, MD, et al.
Published: (2022-12-01)

Ziv-aflibercept in Diabetic Macular Edema: Relation of Subfoveal Choroidal Thickness with Visual and Anatomical Outcomes
by: Siamak Moradian, et al.
Published: (2023-04-01)

Macular Hole Surgery in the Case of Wet Age-Related Macular Degeneration Treated with Intravitreal Aflibercept
by: Agnieszka Nowosielska
Published: (2019-10-01)